February 2005

Biotech Buyout Binge Continues

February 28, 2005

For the second week in a row, buyout rumors and merger speculation sent a number of biotech and specialty pharmaceutical shares higher. Share this page

Read the full article →

Ad Changes Ahead for Controversial Drugs

February 25, 2005

Ad executives and drug company officials say changes in advertising strategies are almost a certainty in the wake of the Vioxx and Celebrex news and new studies showing a consumer backlash.

Read the full article →

Drug Patent Approvals

February 22, 2005

Newsletters alert you to new drug patent approvals.

Read the full article →

U.N. Calls for Clone Ban

February 22, 2005

The United Nations has called on countries to ban all forms of human cloning “incompatable with human dignity.” The American religious right claims victory, but others say the declaration is the result of political maneuvering influenced by pressure from the United States.

Read the full article →

Will California’s Stem Cell Initiative Reap Royalties?

February 19, 2005

When the backers of California’s stem cell initiative were seeking voter support last year, they not only promised cures for dread diseases, but also licensing revenue for the state. A statement posted on the initiative proponents’ CuresforCalifornia.com Web site says that ‘California will benefit for decades from patents and royalties that result from the research.’ [...]

Read the full article →

FDA Plans New Board To Monitor Drug Safety

February 16, 2005

The Food and Drug Administration will create an independent board to more aggressively monitor the safety of drugs on the market as part of an effort to restore public confidence in the nation’s prescription drug supply, Health and Human Services Secretary Mike Leavitt announced yesterday.

Read the full article →

More Roadblocks Ahead For Pharma in 2005?

February 15, 2005

The pharmaceutical industry was traumatized in 2004 when Merck had to withdraw its $2.5 billion COX-2 inhibitor Vioxx from the market due to potentially lethal side effects. Pharmaceutical companies are already struggling to deal with increasing generic competition and stringent approval standards in an effective manner. Will the aftereffects of a disastrous 2004 hamper industry [...]

Read the full article →

Genetically Modified IP Launched

February 10, 2005

Genetically Modified IP Launched A paper appearing in this week’s edition of Nature is antiseptically entitled: ‘Gene transfer to plants by diverse species of bacteria.’ But the information that lies within may herald a revolution in biology.

Read the full article →

From the laboratory to the investment fund

February 8, 2005

From the laboratory to the investment fund How two Chilean scientists turned a graduate thesis into a business that is helping salmon and ham producers

Read the full article →

Biotech: A Big Future Behind It?

February 7, 2005

Biotech: A Big Future Behind It? Despite a bumpy 2004, the rush to market hasn’t abated. The key for this crop of newcomers: Holding investors’ attention?

Read the full article →

← Previous Entries